Director at TScan Therapeutics (NASDAQ: TCRX) granted 67,000 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

TScan Therapeutics director Gabriela Gruia received a grant of stock options as part of her compensation. The award covers 67,000 options to buy Voting Common Stock at an exercise price of $0.9946 per share and expires on May 20, 2036.

According to the terms, these options will vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, provided she continues in service through that date. This filing reflects an equity grant, not an open‑market purchase or sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gruia Gabriela

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 67,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 67,000 options Exercise price: $0.9946 per share Underlying shares: 67,000 shares +3 more

6 metrics

Options granted 67,000 options Stock Option (Right to Buy) awarded to director

Exercise price <money>$0.9946</money> per share Exercise price for Voting Common Stock under option

Underlying shares 67,000 shares Voting Common Stock underlying granted options

Post-grant option holdings 67,000 options Total derivative securities following this transaction

Vesting date trigger <date>May 20, 2027</date> Latest vesting date, or earlier at next annual meeting

Expiration date <date>May 20, 2036</date> Option expiration for this grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.9946"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-05-20T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gruia Gabriela

(Last)

(First)

(Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.9946	05/20/2026		A		67,000		⁽¹⁾	05/20/2036	Voting Common Stock	67,000	$0.00	67,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Zoran Zdraveski, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did TScan Therapeutics (TCRX) disclose in this Form 4 filing?

TScan Therapeutics reported that director Gabriela Gruia received a grant of 67,000 stock options. These options are part of her compensation package and give her the right to buy Voting Common Stock at a fixed exercise price if vesting conditions are met.

How many stock options did Gabriela Gruia receive from TScan Therapeutics (TCRX)?

Gabriela Gruia was granted 67,000 stock options. Each option relates to one share of Voting Common Stock, giving her the potential to purchase 67,000 shares if she exercises all options after they vest and before they expire.

What is the exercise price of the TScan Therapeutics (TCRX) stock options granted?

The stock options granted to Gabriela Gruia have an exercise price of $0.9946 per share. This means she can buy shares at that price once the options vest and before they expire, regardless of the market price at that time.

When do Gabriela Gruia’s TScan Therapeutics (TCRX) options vest?

The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders. Vesting is conditional on her continued service with TScan Therapeutics through the applicable vesting date.

When do the TScan Therapeutics (TCRX) options granted to Gabriela Gruia expire?

These options expire on May 20, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Voting Common Stock from TScan Therapeutics under this grant.

Does this TScan Therapeutics (TCRX) Form 4 show any stock being bought or sold on the market?

No, the Form 4 reports a grant of stock options, not an open-market trade. It reflects a compensation-related award giving future purchase rights, rather than an immediate purchase or sale of TScan Therapeutics shares in the market.